Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer
Publication date: November 2026 Source: The Lancet Oncology, Volume 27, Issue 11 Author(s): Ian F Tannock, Michael Brundage, Christopher M Booth, Nathan I Cherny, Corneel Coens, Elizabeth A Eisenhauer, Jan Geissler, Johannes M Giesinger, Bishal Gyawali, Sjoukje F Oosting, Gregory R Pond, Jaap C Reijneveld, Enrique Soto-Perez-de-Celis, Michelle Tregear, Winette T A van der Graaf, Brooke E Wilson, Madeline L Pe
Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer. // The Lancet Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1470204526003335?dgcid=rss_sd_all
Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer. The Lancet Oncology. https://www.sciencedirect.com/science/article/pii/S1470204526003335?dgcid=rss_sd_all
“Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer.” The Lancet Oncology.
@article{article68964,
title = {Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer},
journal = {The Lancet Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1470204526003335?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment